Objective: To conclusively test for a specific association between the biological marker 25-hydroxy-vitamin D 3 , a transcriptionally active hormone produced in human skin and liver, and the prevalence and severity of Parkinson disease (PD).
Our interest in vitamin D in Parkinson disease (PD) was sparked when an unbiased genomewide expression screen indicated increased expression of the vitamin D receptor (VDR) gene in the blood of patients with PD. 1 Reduced serum levels of the major vitamin D metabolite, total 25-hydroxy-vitamin D (25[OH]D), were observed in several small cross-sectional studies of patients with PD 2 and were more pronounced than in Alzheimer disease. 3 These studies, however, disagreed on whether vitamin D deficiency in PD relates to disease severity. 2, 3 A tantalizing signal linking serum vitamin D to risk of developing PD emerged in a population-based cohort study, although the number of incident cases was small. 4 It was found that 25 [OH]D 3 attenuates 6-hydroxydopamine-induced neurotoxicity, 5 and polymorphisms in the VDR gene have been associated with PD in some studies, 6, 7 but not others (see www.pdgene.org).
Endogenous vitamin D 3 is produced through photochemical action of sunlight on 7dehydrocholesterol in human skin. Hydroxylation steps produce the major vitamin D hormones, 25-hydroxy-vitamin D 3 and the biologically more active 1,25-hydroxy-vitamin D 3 , respectively. These hormones transactivate target genes in the brain and other organs through the nuclear receptor VDR (reviewed in ref. 8) . Vitamin D 2 , by contrast, is produced in yeast and mushrooms, not humans. Very few foods naturally contain meaningful levels of vitamin D, but milk, orange juice, and cereal fortified with either vitamin D 2 or D 3 are widely available. 9 Does vitamin D matter for patients with PD? In this study, we used liquid chromatography/tandem mass spectrometry to investigate an association specifically between deficiency of the transcriptionally active human hormone 25[OH]D 3 and PD.
METHODS Study population. Three hundred eighty-eight patients with PD and 283 control subjects without neurologic disease nested in the Harvard Biomarker Study population who met eligibility criteria as of 2010 were included. The Harvard NeuroDiscovery Center Biomarker Study (HBS) is a Harvardwide longitudinal case-control study designed to accelerate the discovery and validation of molecular diagnostics that track or predict progression of early-stage PD. Inclusion criteria for PD cases were age 21 years or older, diagnosis of PD according to UK PD Society Brain Bank criteria (modified as described in ref. 10) or according to movement disorders specialist assessment, and Mini-Mental State Examination scores .21 or next of kin present to provide informed consent. Exclusion criteria for PD cases were diagnosis of a blood or bleeding disorder, known hematocrit ,30%, known active ulcer, or active colitis. Inclusion criteria for healthy controls were no current diagnosis or history of a neurologic disease, and age 21 years or older. Exclusion criteria for controls were the same as for cases. Controls were comparable to the PD cases in that they were drawn from the same source population and could be identified as cases, if they had disease. Diagnosis of cases and controls was monitored during follow-up to ensure high diagnostic accuracy. Clinical disease severity was assessed in an operationally defined "on state" based on expert judgment at the time of the visit as in refs. 11-13. Patients thus were not necessarily at the peak of optimal response (true on state) or in their true off state (at least 24 hours and as much as 4 weeks after the last dose). Of the 388 patients with PD, 296 had a second study visit (mean time from enrollment 6 SD, 12.6 6 2.4 months), and 295 had a third study visit (25.81 6 5.0 months).
Standard protocol approvals and patient consents. Informed consent was obtained from all participants. The study protocol was approved by the institutional review boards of Brigham and Women's Hospital and Massachusetts General Hospital.
Liquid chromatography/tandem mass spectrometry. Data analysis. Vitamin D measures and total Unified Parkinson's Disease Rating Scale (UPDRS) scores were log-transformed for purposes of the significance tests to reduce skewness and violation of normality assumptions. Baseline characteristics of cases and controls were examined (table 1), including factors known to affect vitamin D status such as age, sex, race, body mass index, smoking status, vitamin D supplementation, season at blood draw, and latitude of the participants' residence (the latter 2 serve as proxies for sunshine exposure). Less than 5% of cases and ,9% of controls had missing values for any of these covariates. Baseline inequalities were found for age, sex, race, and vitamin D supplementation and adjusted for in all multivariate analyses. There was no material baseline inequality for season of blood draw and latitude of the participants' residence. For the crosssectional analysis, multivariate logistic regression was used to test for associations between vitamin D and PD. Values of 25[OH]D 3 (total 25[OH]D) were missing for 5 (2) cases and 2 (2) controls; subjects with missing values were excluded. General linear regression models were used for testing associations of vitamin D with UPDRS scores, duration of PD illness, and Hoehn and Yahr (HY) stage. For the longitudinal analysis, mixed intercept and slope models were used to relate vitamin D levels to UPDRS or HY. Analyses were performed using SAS 9.2 (SAS Institute, Cary, NC), and statistical significance was defined as p , 0.05.
RESULTS
Cases were somewhat younger (mean age 6 SD, 65.7 6 9.6 years for cases vs 68.0 6 10.4 years for controls), included a higher proportion of men (64.4% vs 37.5%), and of Caucasians (97.7% vs 91.9%). Cases reported vitamin D supplementation less frequently than controls (12.6% vs 25.1%). No material differences in body mass index, smoking status, season at blood draw, or latitude of the participants' residence were found. Clinically, cases were early in the disease course with an average modified HY stage of 2.1 6 0.6 and an average total UPDRS score of 31.1 6 14.3.
Plasma levels of 25[OH]D 3 were associated with the prevalence of PD in both univariate and multivariate analyses adjusting for pertinent baseline inequalities such as age, sex, race, and vitamin D supplementation. In the univariate analysis (table 1), specifically 25[OH] D 3 as well as total 25[OH]D levels were lower in plasma of cases compared with controls (28.0 6 11.0 vs 30.6 6 11.1 ng/mL with p 5 0.0034; and 30.5 6 12.0 vs 32.5 6 10.6 ng/mL with p 5 0.032). Although there is no consensus on optimal levels of 25[OH]D as measured in serum, vitamin D deficiency is defined by most experts as a 25[OH]D level of ,20 ng/mL (50 nmol/L). 9 A level of 25[OH]D ,30 ng/mL can be considered to indicate a relative insufficiency of vitamin D, and a level of $30 ng/mL can be considered to indicate sufficient vitamin D. 9 There was vitamin D deficiency in 17.6% of cases (68/388) compared with 9.3% of controls (26/283; p 5 0.002). Furthermore, 47.2% of cases (182/388) were vitamin D insufficient compared with 39.9% of controls (112/283; p 5 0.06). Thus, a substantial number of controls and an even larger proportion of cases had abnormal levels of this essential hormone. Multivariate cross-sectional analysis (table 2) adjusting for pertinent baseline inequalities of age, sex, race, and vitamin D supplementation indicated that low levels of 25[OH]D 3 were associated with an increased disease prevalence and severity. Individuals with levels in the lowest quintile of 25[OH]D 3 values observed in our population had the highest prevalence of PD with an odds ratio of 1.8 with p 5 0.03 (95% confidence interval, 1.06-3.2) compared with individuals with values in the highest quintile (table 2). After adjusting for these covariates, deficiency of total 25[OH]D (levels ,20 ng/mL) remained enriched in PD with p 5 0.03, although the overall relation between total 25[OH]D and PD no longer reached significance (p 5 0.27; table 2 and figure). Exploratory subgroup analyses in male and female study participants confirmed strong and significant associations between 25[OH]D 3 and total 25[OH]D levels and PD in male study participants, whereas in female subjects, concordant trends were observed that did not reach statistical significance. Previous studies examining the relation between measures of clinical disease severity and vitamin D levels proved inconsistent and controversial. 15 The results obtained in our study showed a relation between higher (worse) total UPDRS scores and specifically low 25[OH]D 3 as well as low total 25[OH]D levels with p 5 0.0096 and 0.02, respectively (table 2, figure) . Importantly, even in the prospective, longitudinal analysis, low baseline 25[OH]D 3 as well as total 25[OH]D levels were associated with higher UPDRS scores during the clinical follow-up (table 3) . Thus, lower vitamin D levels are found in individuals with more advanced disease severity as measured by the "gold standard," the clinical total UPDRS scale. Associations with the HY scale, an alternate measure of disease severity, failed to reach statistical significance (tables 2 and 3, figure) . DISCUSSION Fractures from falls are a major and common complication of PD. While fractures always lead to a decline in function and quality of life in patients with PD, the most threatening potential consequences are a downward spiral of hospitalization, decompensation, and even death. Endogenous vitamin D enhances bone mineralization. Vitamin D supplementation (at doses higher than 400 IU/d) reduces fractures by at least 20% in individuals older than age 65. 16 Should vitamin D management be part of a personalized medicine approach for patients with PD?
This large cross-sectional and longitudinal study of 388 cases and 283 controls nested in the HBS population, combined with consistent results from multiple small, independent association studies, 2,3 provides compelling evidence that at least 17% of all patients with PD seen at 2 academic tertiary care centers are vitamin D deficient-almost twice the prevalence of vitamin D deficiency in controls of similar ages without PD. Furthermore, vitamin D deficiency was associated with total UPDRS score (indicating more advanced severity of disease) after adjusting for confounding variables in the cross-sectional analysis, and prospectively, during the follow-up period.
Beyond the rather clear-cut immediate clinical implications of vitamin D deficiency in patients with PD, Table 2 Cross-sectional analysis for associations between 25[OH]D 3 vitamin D-mediated transactivation of VDR target genes is poised for an important role in dopamine neuron biology and may offer clues for disease modification in PD. 8 Both the vitamin D receptor and 1a-hydroxylase (which activates 25[OH]D 3 conversion into the active hormone) are expressed in the human brain, with the strongest immunohistochemical staining observed in dopaminergic neurons within the substantia nigra and in the hypothalamus. 17 Pretreatment with 1,25[OH]D 3 partially restores tyrosine hydroxylase expression and protects against dopamine depletion in substantia nigra of 6-hydroxydopamine-lesioned rats. 5, 18 This study has several strengths and limitations. Distinct vitamin D metabolites were for the first time specifically assayed in PD. Potential confounding factors (age, sex, race, body mass index, season at blood draw, latitude of residence, smoking, as well as vitamin D supplementation) were examined and adjusted for as indicated. The HBS was specifically designed to minimize bias from sample processing by collecting, handling, and analyzing specimens of cases and controls in a standardized and blinded manner according to rules of evidence (reviewed in ref. 19 ). Approximately 90% of cases enrolled in the HBS diagnosed with PD by a neurology board-certified, movement disorders fellowship-trained neurologist met modified UK PD Society Brain Bank criteria, 10 with accuracy further enhanced by longitudinal annual movement disorders specialist reassessments. Controls were comparable to the PD cases in that they were drawn from the same source population and could be identified as a case, if they had disease. There are several limitations. Despite these provisions, lurking bias is a key threat to all biomarker studies, including ours. Second, our study represents patients and controls receiving care at Massachusetts General Hospital and Brigham and Women's Hospital, not the general US population. Evaluation in minority populations that may be at even higher risk of vitamin D deficiency will be necessary. Third, a previous study of 157 early-stage de novo patients (not treated with dopamine replacement medications) found 21% total 25[OH]D deficiency 15 compared with the 17.6% found in the current study. The vast majority of patients in our study were also at an early stage (HY of #2.5), but only 12.9% were not receiving PD medications. Thus, however unlikely in the context of previous work, a subtle medication bias can not be completely ruled out. Fourth, association does not imply causation.
The goal of our study was to evaluate vitamin D status in patients with PD who are vulnerable to falls and fractures, not to investigate the cause of vitamin D deficiency. It remains to be seen whether PD predisposes to vitamin D deficiency (conceivably by limiting outdoor activities) or whether vitamin D deficiency modifies the disease as suggested by preclinical studies 5, 8, 17, 18 and a small randomized placebo-controlled clinical trial 20 reported while this manuscript was in preparation. Fifth, this study did not directly evaluate the effect of vitamin D deficiency (or supplementation) on clinical outcomes such as fracture risk in patients with PD, a goal for further investigation. These data suggest that patients with PD should be included among the categories of individuals at high risk of vitamin D deficiency who warrant vitamin D biomarker measurement and vitamin D treatment. Vitamin D clearly is an excellent target for therapies designed to improve the quality of life of thousands of vitamin D-deficient patients with PD in North America alone -with a potentially major impact on public health and health care cost savings. Moreover, the tantalizing, but inconclusive, epidemiologic, biochemical, transcriptional, and genetic links among vitamin D, vitamin D target genes, and dopamine neuropathology warrant mechanistic and further prospective exploration.
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